首页> 外文期刊>International Journal of Pharmaceutics >Preparation of a solid self-microemulsifying drug delivery system by hot-melt extrusion
【24h】

Preparation of a solid self-microemulsifying drug delivery system by hot-melt extrusion

机译:用热熔挤压制备固体自微乳化药物递送系统

获取原文
获取原文并翻译 | 示例
           

摘要

Hot-melt extrusion (HME) has gained increasing attention in the pharmaceutical industry; however, its potential in the preparation of solid self-emulsifying drug delivery systems (S-SMEDDS) is still unexplored. This study sought to prepare enteric S-SMEDDS by HME and evaluate the effects of the process and formulation variables on S-SMEDDS properties via Box-Behnken design. Liquid SMEDDS were developed, and carvedilol was used as a class II model drug. Mean size, polydispersity index (PdI) and zeta potential of the resulting microemulsions were determined. The extrudates were then obtained by blending the lipid mixture and HPMCAS using a twin-screw hot-melt extruder. SEM, optical microscopy and PXRD were used to characterize the extrudates. In vitro microemulsion reconstitution and drug release were also studied. L-SMEDDS gave rise to microemulsions with low mean size, PdI and zeta potential (140.04 +/- 7.22 nm, 0.219 +/- 0.011 and -9.77 +/- 0.86 mV). S-SMEDDS were successfully prepared by HME, and an HMPCAS matrix was able to avoid microemulsion reconstitution and retain drug release in pH 1.2 (12.97%-25.54%). Conversely, microemulsion reconstitution and drug release were gradual in pH 6.8 and complete for some formulations. Extrudates prepared at the lowest drug concentration and highest temperature and recirculation time promoted a complete and rapid drug release in pH 6.8 giving rise to small and uniform microemulsion droplets.
机译:热熔挤压(HME)在制药行业中越来越受到关注;然而,它在制备固体自乳化药物递送系统(S-SMEDDS)中的潜力仍未探索。本研究试图通过HME制备肠溶S-SMEDDS,并通过Box-Behnken设计评估过程和配方变量对S-SMEDDS属性的影响。液体Smedds开发出来,卡维地洛用作II类模型药物。确定所得微乳液的平均尺寸,多分散指数(PDI)和Zeta电位。然后通过使用双螺杆热熔挤出机混合脂质混合物和HPMCA来获得挤出物。 SEM,光学显微镜和PXRD用于表征挤出物。还研究了体外微乳液重构和药物释放。 L-SMEDDS产生低平均尺寸,PDI和Zeta电位的微乳液(140.04 +/- 7.22 nm,0.219 +/- 0.011和-9.77 +/- 0.86 mV)。 S-SMEDDS由HME成功制备,HMPCAS基质能够避免微乳液重构,并在pH 1.2中保留药物释放(12.97%-25.54%)。相反,微乳液重构和药物释放在pH6.8中逐渐逐渐逐渐曲线,并完成一些配方。在最低药物浓度和最高温度和再循环时间下制备的挤出物促进了pH 6.8中的完全和快速的药物释放,从而产生小和均匀的微乳液液滴。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号